EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial

Mariangela Rondanelli iD, Clara Gasparri iD, Alessandro Cavioni, Claudia Sivieri, Gaetan Claude Barrile iD, Francesca Mansueto, Simone Perna iD

Nutrients · 30.04.2024 · 16 (9) · 1369

DOI: 10.3390/nu16091369 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 30.04.2024. Verfasst von Mariangela Rondanelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy. Hauptthemen laut MEDLINE: Dietary Supplements, Sarcopenia, Carnosine, Lactoferrin. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adequate diet, physical activity, and dietary supplementation with muscle-targeted food for special medical purposes (FSMP) or dietary supplement (DS) are currently considered fundamental pillars in sarcopenia treatment. The aim of this study is to evaluate the effectiveness of a DS (containing hydroxy-methyl-butyrate, carnosine, and magnesium, for its action on muscle function and protein synthesis and butyrate and lactoferrin for their contribution to the regulation of gut permeability and antioxidant/anti-inflammation activity) on muscle mass (assessed by dual X-ray absorptiometry (DXA)), muscle function (by handgrip test, chair test, short physical performance battery (SPPB) test, and walking speed test), inflammation (tumor necrosis factor-alpha (TNF-a), C-reactive protein (CRP), and visceral adipose tissue (VAT)) and gut axis (by zonulin). A total of 59 participants (age 79.7 ± 4.8 years, body mass index 20.99 ± 2.12 kg/m2) were enrolled and randomly assigned to intervention (n = 30) or placebo (n = 28). The skeletal muscle index (SMI) significantly improved in the supplemented group compared to the placebo one, +1.02 (CI 95%: −0.77; 1.26), p = 0.001; a significant reduction in VAT was observed in the intervention group, −70.91 g (−13.13; −4.70), p = 0.036. Regarding muscle function, all the tests significantly improved (p = 0.001) in the supplemented group compared to the placebo one. CRP, zonulin, and TNF-alpha significantly decreased (p = 0.001) in intervention, compared to placebo, −0.74 mg/dL (CI 95%: −1.30; −0.18), −0.30 ng/mL (CI 95%: −0.37; −0.23), −6.45 pg/mL (CI 95%: −8.71; −4.18), respectively. This DS improves muscle mass and function, and the gut muscle has emerged as a new intervention target for sarcopenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dietary SupplementsSarcopeniaCarnosineLactoferrinMagnesiumMuscle, SkeletalPermeabilityHumansMaleAgedFemaleAged, 80 and overValeratesTumor Necrosis Factor-alphaButyratesDouble-Blind MethodHaptoglobinsC-Reactive ProteinProtein Precursors

Stichwörter der Autor:innen

C-reactive proteinTNF-abody compositionbutyratecarnosinehydroxy-methyl-butyratelactoferrinmagnesiumsarcopeniazonulin

Substanzen

CarnosineLactoferrinMagnesiumValeratesTumor Necrosis Factor-alphaButyratesbeta-hydroxyisovaleric acidzonulinHaptoglobinsC-Reactive Protein

Autor:innen und Institutionen

  • Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy.
  • Endocrinology and Nutrition Unit, Azienda di Servizi alla Persona ''Istituto Santa Margherita'', University of Pavia, 27100 Pavia, Italy.
  • Division of Human Nutrition, Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20019 Milano, Italy.

ORCID-Profile: Mariangela Rondanelli, Clara Gasparri, Gaetan Claude Barrile, Simone Perna

Zitieren

APA

Rondanelli, M., Gasparri, C., Cavioni, A., Sivieri, C., Barrile, G. C., Mansueto, F., & Perna, S. (2024). A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial. Nutrients, 16(9), 1369. https://doi.org/10.3390/nu16091369

Vancouver

Rondanelli M, Gasparri C, Cavioni A, Sivieri C, Barrile GC, Mansueto F, et al. A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial. Nutrients. 2024;16(9):1369. doi:10.3390/nu16091369

BibTeX
@article{Rondanelli2024,
  author = {Rondanelli, Mariangela and Gasparri, Clara and Cavioni, Alessandro and Sivieri, Claudia and Barrile, Gaetan Claude and Mansueto, Francesca and Perna, Simone},
  title = {A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial},
  journal = {Nutrients},
  year = {2024},
  volume = {16},
  number = {9},
  pages = {1369},
  doi = {10.3390/nu16091369}
}
Kostenlos starten →